Weichteilsarkome: neue Erkenntnisse und Entwicklungen

Schlüsselwörter

Weichteilsarkom - Chemotherapie - Hyperthermie

Keywords

sarcoma - chemotherapy - hyperthermia

• Literatur

• 1 Biau DJ, Ferguson PC, Turcotte RE et al. Adverse effect of older age on the recurrence of soft tissue sarcoma of the extremities and trunk. J Clin Oncol 2011; 29: 4029-4035
• 2 Bui-Nguyen B, Ray-Coquard I, Chevreau C et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients. Ann Oncol 2012; 23: 777-784
• 3 Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 05) v198-203
• 4 Chawla SP, Blay J, Ray-Coquard IL et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011; 29 (suppl; abstr 10005)
• 5 Chawla SP, Staddon AP, Baker LH et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30: 78-84
• 6 García-Del-Muro X, López-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29: 2528-2533
• 7 Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012; 23: 771-776
• 8 Herrmann K, Benz MR, Czernin J et al. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 2012; 18: 2024-2031
• 9 Issels RD, Lindner LH, Verweij J et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561-570
• 10 Italiano A, Mathoulin-Pelissier S, Cesne AL et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011; 117: 1049-1054
• 11 Katz D, Boonsirikamchai P, Choi H et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin Sarcoma Res 2012; 2: 2
• 12 National Comprehensive Cancer Network (NCCN) Guidelines. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Updated May 24, 2012
• 13 Ray-Coquard I, Montesco MC, Coindre JM et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012; Feb 13
• 14 Ray-Coquard IL, Cesne AL, Staddon AP et al. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (> 24 months) overall survival results. Proc ASCO 2012; abstr 10010
• 15 van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886